Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

@article{Harris2006MolecularSO,
  title={Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342},
  author={Lyndsay N. Harris and Gloria Broadwater and Nancy U. Lin and Alexander Miron and Stuart J. Schnitt and David Z Cowan and Jonathan F. Lara and Ira J. Bleiweiss and Donald A. Berry and Matthew J. Ellis and Daniel F. Hayes and Eric P. Winer and Lynn G. Dressler},
  journal={Breast Cancer Research},
  year={2006},
  volume={8},
  pages={R66 - R66}
}
The response to paclitaxel varies widely in metastatic breast cancer. We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status. Among 474 women randomly assigned to paclitaxel at a dose of 175, 210, or 250 mg/m2, adequate primary tumor tissue was available from 175. Immunohistochemistry with two antibodies and fluorescence in situ hybridization… CONTINUE READING
80 Citations
46 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: results from a pilot study in CALGB 9342

  • LN Harris, C Perou, +8 authors M Ellis
  • ASCO Meeting Abstracts
  • 2005

Understanding racial differences in outcome from metastatic breast cancer (MBC): A pooled analysis of Cancer and Leukemia Group B (CALGB) 9342 and 9840 [abstract 3097

  • BN CCPolite, GF Fleming, +5 authors EP Winer
  • Breast Cancer Res Treat 2005:3097
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…